Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumari L Andarawewa

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Journal of Radiation Biology|December 7, 2007
New rationales for using TGFbeta inhibitors in radiotherapyKumari L Andarawewa, Jenny Paupert, Anupama Pal, et al.
Cancer Research|December 3, 2005
Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive frontKumari L Andarawewa, Elena R Motrescu, Marie-Pierre Chenard, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 3, 2007
1,25(OH)2D3 inhibits in vitro and in vivo intracellular growth of apicomplexan parasite Toxoplasma gondiiRohan Rajapakse, Béatrice Uring-Lambert, Kumari L Andarawewa, et al.
Oncogene|June 13, 2003
Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factorsFabien Alpy, Anne Boulay, Christel Moog-Lutz, et al.
International Journal of Cancer|October 23, 2004
Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinasesVincent Dive, Kumari L Andarawewa, Anne Boulay, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2011
Lack of radiation dose or quality dependence of epithelial-to-mesenchymal transition (EMT) mediated by transforming growth factor βKumari L Andarawewa, Sylvain V Costes, Ignacio Fernandez-Garcia, et al.
Cancer Research|October 3, 2003
Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progressionKumari L Andarawewa, Anne Boulay, Régis Masson, et al.
Cancer Research|September 19, 2007
Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transitionKumari L Andarawewa, Anna C Erickson, William S Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Integrin agonists as adjuvants in chemotherapy for melanomaMartin A Schwartz, Kevin McRoberts, Matthew Coyner, et al.
Pigment Cell & Melanoma Research|September 30, 2014
Integrin adjunct therapy for melanomaKumari L Andarawewa, Konstadinos Moissoglu, Chang Sup Lee, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Radiation Biology|December 7, 2007
New rationales for using TGFbeta inhibitors in radiotherapyKumari L Andarawewa, Jenny Paupert, Anupama Pal, et al.
Cancer Research|December 3, 2005
Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive frontKumari L Andarawewa, Elena R Motrescu, Marie-Pierre Chenard, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 3, 2007
1,25(OH)2D3 inhibits in vitro and in vivo intracellular growth of apicomplexan parasite Toxoplasma gondiiRohan Rajapakse, Béatrice Uring-Lambert, Kumari L Andarawewa, et al.
Oncogene|June 13, 2003
Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factorsFabien Alpy, Anne Boulay, Christel Moog-Lutz, et al.
International Journal of Cancer|October 23, 2004
Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinasesVincent Dive, Kumari L Andarawewa, Anne Boulay, et al.
International Journal of Radiation Oncology, Biology, Physics|February 12, 2011
Lack of radiation dose or quality dependence of epithelial-to-mesenchymal transition (EMT) mediated by transforming growth factor βKumari L Andarawewa, Sylvain V Costes, Ignacio Fernandez-Garcia, et al.
Cancer Research|October 3, 2003
Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progressionKumari L Andarawewa, Anne Boulay, Régis Masson, et al.
Cancer Research|September 19, 2007
Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transitionKumari L Andarawewa, Anna C Erickson, William S Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Integrin agonists as adjuvants in chemotherapy for melanomaMartin A Schwartz, Kevin McRoberts, Matthew Coyner, et al.
Pigment Cell & Melanoma Research|September 30, 2014
Integrin adjunct therapy for melanomaKumari L Andarawewa, Konstadinos Moissoglu, Chang Sup Lee, et al.
Pageof 1